{"id":9056,"date":"2020-08-14T11:38:59","date_gmt":"2020-08-14T18:38:59","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9056"},"modified":"2021-04-13T11:39:44","modified_gmt":"2021-04-13T18:39:44","slug":"phase-1-2-study-of-covid-19-rna-vaccine-bnt162b1-in-adults","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/08\/14\/phase-1-2-study-of-covid-19-rna-vaccine-bnt162b1-in-adults\/","title":{"rendered":"Phase 1\/2 Study of COVID-19 RNA Vaccine BNT162b1 in Adults"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"43\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Mulligan et al. report safety, tolerability, and immunogenicity findings from an ongoing placebo-controlled observer-blinded dose escalation study among 45 healthy adults randomized to receive an anti-SARS-CoV-2 vaccine that targets the spike glycoprotein receptor-binding domain (two doses<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">21 days apart). Local reactions and systemic events were generally mild, dose-dependent, and transient. Exceptions included one report of severe pain for a high-dose participant, two reports of grade 3 fever, and one report of sleep disturbance. No serious adverse events were reported.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"43\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">IgG concentrations and neutralizing titers increased with dose level and after a second dose; however, the difference between medium- and high-dose after the first vaccination was not meaningful. As a result, a second high-dose vaccination was not administered. Neutralizing titers were 1.9 to 4.6 times that of a panel of COVID-19 convalescent human sera.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Mulligan et al. (Aug 12, 2020). Phase 1\/2 Study of COVID-19 RNA Vaccine BNT162b1 in Adults.\u00a0<\/span><\/i><i><span data-contrast=\"none\">Nature.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1038\/s41586-020-2639-4\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1038\/s41586-020-2639-4<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mulligan et al. report safety, tolerability, and immunogenicity findings from an ongoing placebo-controlled observer-blinded dose escalation study among 45 healthy adults randomized to receive an anti-SARS-CoV-2 vaccine that targets the spike glycoprotein receptor-binding domain (two doses\u00a021 days apart). Local reactions and systemic events were generally mild, dose-dependent, and transient. Exceptions included one report of severe&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/08\/14\/phase-1-2-study-of-covid-19-rna-vaccine-bnt162b1-in-adults\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[31],"class_list":["post-9056","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9056"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9056\/revisions"}],"predecessor-version":[{"id":9057,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9056\/revisions\/9057"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9056"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}